

DOCKET NO.: C1039.70073US00

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Krieg et al.

Serial No.:

10/743,625

Confirmation No.:

9416

Filed:

December 22, 2003

For:

IMMUNOSTIMULATORY NUCLEIC ACID

Examiner:

Nita M. Minnifield

Art Unit:

1645

#### CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 17th day of December, 2007.

Lisa M. Rosenberg

#### MAIL STOP AMENDMENT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check in the amount of \$180.00 is enclosed to cover the filing fee. If the fee is insufficient, the balance may be charged to Deposit Account 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

Helen C. Lockhart, Ph.D., Reg. No.: 39,248

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: C1039.70073US00 Date: December 172007

xNDDx



DOCKET NO.: C1039.70073US00

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Krieg et al.

Serial No.:

10/743,625

Confirmation No.:

9416

Filed:

December 22, 2003

For:

IMMUNOSTIMULATORY NUCLEIC ACID

Examiner:

Nita M. Minnifield

Art Unit:

1645

#### **CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

Lisa M. Rosenberg

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

# PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

Conf. No.: 9416

# PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

Serial No.	Filing Date	Inventor(s)	Docket No.
11/706,561	02-15-2007	Uhlmann et al.	*C1041.70046US02
11/725,339	03-19-2007	Schetter et al.	*C1041.70019US01
11/810,353	06-05-2007	Krieg et al.	*C1039.70048US25
11/901,712	09-17-2007	Schetter et al.	C1039.70069US01

<sup>\*</sup>A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

The Applicant would like to bring to the Examiner's attention the following other information:

Office Communication mailed 09/21/2000 for Application No. 09/337,584 (C1039.70020US00)
Office Communication mailed 07/30/2001 for Application No. 09/337,584 (C1039.70020US00)
Office Communication mailed 05/03/2002 for Application No. 09/337,584 (C1039.70020US00)
Office Communication mailed 06/23/2004 for Application No. 09/337,584 (C1039.70020US00)
Office Communication mailed 01/13/2005 for Application No. 09/337,584 (C1039.70020US00)
Office Communication mailed 06/28/2005 for Application No. 09/337,584 (C1039.70020US00)
Office Communication mailed 03/29/2006 for Application No. 09/337,584 (C1039.70020US00)
Office Communication mailed 04/09/2007 for Application No. 10/921,086 (C1039.70020US01)
Office Communication mailed 08/17/2007 for Application No. 10/921,086 (C1039.70020US01)
Office Communication mailed 10/07/2005 for Application No. 10/817,165 (C1039.70048US02)
Office Communication mailed 12/28/2006 for Application No. 10/817,165 (C1039.70048US02)
Office Communication mailed 12/28/2006 for Application No. 10/817,165 (C1039.70048US02)

Serial No.: 10/743,625 - 3 - Art Unit: 1645

Conf. No.: 9416

Office Communication mailed 07/27/2007 for Application No. 10/817,165 (C1039.70048US02) Office Communication mailed 12/13/2006 for Application No. 10/847,642 (C1039.70048US04) Office Communication mailed 04/20/2007 for Application No. 10/847,642 (C1039.70048US04) Office Communication mailed 01/17/2007 for Application No. 10/894,657 (C1039.70048US09)

The Applicant would like to bring to the Examiner's attention the following other information, whose relevance is discussed in Part III below:

# <u>PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited</u>

The following are remarks concerning the other information cited:

US patent application 09/337,584 with claims directed to the treatment of asthma is now in an Interference (No. 105,526). Copies of papers filed with respect to that Interference are submitted herewith. If the Examiner would like any additional information on this subject, she is encouraged to contact Applicant's representative at the number listed below.

# PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

Serial No.: 10/743,625 -4 - Art Unit: 1645

Conf. No.: 9416

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:

Helen C. Lockhart, Ph.D., Reg. No. 39,248

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: C1039.70073US00 Date: December 17, 2007

**xNDDx**